Fosphenytoin

Summary

Fosphenytoin (CHEMBL1201336) is an approved small molecule (ATC N03AB05); indicated across 2 conditions including epilepsy.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N03AB05
• Indications: 2 conditions
• Clinical trials: 8
• Chemistry: 362.27 Da · C16H15N2O6P

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201336
Name	Fosphenytoin
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	56339
ATC	N03AB05
Molecular formula	C16H15N2O6P
Molecular weight	362.27
InChIKey	XWLUWCNOOVRFPX-UHFFFAOYSA-N

SMILES: C1=CC=C(C=C1)C2(C(=O)N(C(=O)N2)COP(=O)(O)O)C3=CC=CC=C3

IUPAC name: (2,5-dioxo-4,4-diphenylimidazolidin-1-yl)methyl dihydrogen phosphate

Also known as: Fosfenitoina, Fosphenytoin, Fosphenytoine, Np-06, fosphenytoin, SID170465016, FOSPHENYTOIN, Fosphenytoin disodium salt hydrate

Parent form; salt/anhydrous children: CHEMBL919, CHEMBL5205794

Patent coverage: 1,731 distinct patent families (6,707 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
epilepsy	4	MONDO:0005027	EFO:0000474

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 8.

Phase distribution

Phase	Trials
PHASE4	3
PHASE3	3
Not specified	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06403150	PHASE4	ENROLLING_BY_INVITATION	The Efficacy and Safety of Levetiracetam Versus Fosphenytoin in Convulsive Status Epilepticus
NCT00510783	PHASE4	COMPLETED	IV Keppra in the Emergency Department for Prevention of Early Recurrent Seizures
NCT06081283	PHASE4	TERMINATED	Antiseizure Medication in Seizure Networks at Early Acute Brain Injury
NCT00908453	PHASE3	COMPLETED	The Study of NPC-06 - Investigation of Safety, Efficacy and Pharmacokinetics of Fosphenytoin
NCT01870024	PHASE3	COMPLETED	Comparison Between Lorazepam, Clonazepam and Clonazepam + Fosphenytoin for the Treatment of Out-of-hospital Generalized Status Epilepticus
NCT01960075	PHASE3	COMPLETED	Established Status Epilepticus Treatment Trial
NCT01110187	Not specified	TERMINATED	A Pilot Study of NSICU Assessment of Seizure Prophylaxis With Lacosamide
NCT03712254	Not specified	COMPLETED	Phenytoin as Treatment for Acute Exacerbations of Trigeminal Neuralgia - a Prospective Systematic Study of 20 Patients

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

PharmGKB dosing guidelines (1) — CPIC / DPWG genotype-guided dosing for this drug (drug × pharmacogene):

Guideline	Source	Gene(s)	Dosing	Recommendation
Annotation of CPIC Guideline for fosphenytoin, phenytoin and CYP2C9, H	CPIC	CYP2C9;HLA-B	yes	yes

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).